INDO-MIM Limited – Investor Presentation Summary

Key Operational Highlights

  • Revenue from operations reached ₹2,490.6 crore for H1 FY27, an increase of ₹263.8 crore from H1 FY26 (₹2,226.8 crore).
  • The cash conversion cycle was 417 days for H1 FY27, higher than the 324 days in H1 FY26, indicating increased working capital intensity.
  • Key drivers of operational performance included strong growth in the MIM product group (+19.8% YoY) and broad-based growth across end-user segments.

Segment-wise Performance

Revenue by Product Group (₹ crore):

  • MIM: ₹1,500.1 crore (60% of mix), +19.8% YoY
  • IC: ₹477.2 crore (19% of mix), +36.0% YoY
  • Machining: ₹188.2 crore (8% of mix), +55.4% YoY
  • Medical Devices: ₹23.2 crore (1% of mix), -7.1% YoY
  • Powders: ₹20.8 crore (1% of mix), +25.1% YoY
  • Others: ₹281.0 crore (11% of mix), -39.0% YoY

Revenue by End-User Segment (₹ crore):

  • AEPG (Aerospace): ₹223.9 crore (9% of mix), +31.5% YoY
  • APG (Automotive): ₹615.6 crore (25% of mix), +19.4% YoY
  • CPG (Consumer): ₹389.5 crore (16% of mix), +46.2% YoY
  • DPG (Defence): ₹493.8 crore (20% of mix), +19.3% YoY
  • MPG (Medical): ₹475.3 crore (19% of mix), +22.7% YoY
  • Powder, tools, traded: ₹24.4 crore (1% of mix), +11.2% YoY
  • ECM (electronics): ₹268.1 crore (11% of mix), -40.5% YoY

Explanation of significant changes in segment performance: Higher defence and medical contribution, including tooling income, contributed to margin expansion. The decline in ECM revenue was significant at -40.5%.

Financial Highlights

Consolidated Financials (₹ crore):

  • Revenue: ₹2,490.6
  • EBITDA: ₹803.4
  • PAT: ₹455.3
  • Basic EPS (₹): 9.34
  • EBITDA Margin: 32.0%
  • Net Margin: 18.2%

YoY comparison:

  • Revenue: +11.8% vs H1 FY26
  • EBITDA: +37.9% vs H1 FY26
  • PAT: +57.0% vs H1 FY26
  • EBITDA Margin: +630 bps vs H1 FY26 (25.7%)
  • Net Margin: +540 bps vs H1 FY26 (12.8%)

Standalone Financials (₹ crore):

  • Revenue: ₹2,073.1, +7.5% YoY
  • EBITDA: ₹741.6, +15.7% YoY
  • PAT: ₹443.5, +51.7% YoY
  • Basic EPS (₹): 9.09, +49.8% YoY
  • EBITDA Margin: 35.5%, +280 bps YoY
  • Net Margin: 21.2%, +630 bps YoY

Drivers of financial performance: Strong operating leverage with EBITDA growth significantly outpacing revenue growth, indicating improved cost efficiency and enhanced earnings quality.

Geographical Revenue Split

Not Specified

Balance Sheet Snapshot

  • Debt-to-equity: 0.27x in H1 FY27, down from 0.50x in previous period
  • ROCE: 36.5% in H1 FY27, up 570 bps
  • ROE: 26.3% in H1 FY27

Financial Health Insights: The company demonstrated higher returns and lower leverage with significantly improved ROCE and reduced debt-to-equity ratio.

Capex & Cash Flow Health

  • Operating cash flow: ₹444.3 crore in H1 FY27 (vs H1 FY26: (₹567.1 crore))
  • Free cash flow: ₹31.2 crore in H1 FY27 (vs H1 FY26: (₹355.9 crore))
  • CFO/EBITDA: 55% in H1 FY27 (vs H1 FY26: (97.4%))

Investment Rationale: Not explicitly stated, but the presentation highlights improved cash flow generation compared to the previous period.

Strategic & R&D Initiatives

The company is positioned as a strategic engineering and manufacturing partner, not merely a component supplier, with a single reporting segment: "Manufacturer of Precision Engineering Components."

Industry Trends & Business Environment

Not Specified

Management Commentary & Growth Outlook

Strategic Outlook: Management's stated normal-course EBITDA margin framework is 20-25% with a PAT margin range of 13-18%. H1 FY27 performance was elevated due to higher defence and medical contribution.

FY Guidance: Management provided full-year FY27 revenue and bottom-line targets and expects to do better than these targets, with a further update planned after Q3 FY27.

Risks and Opportunities: The upside to margins comes from years in which defence or medical revenue carries a higher mix.